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Abstract
DB844 (CPD-594-12), N-methoxy-6-{5-[4-(N-methoxyamidino)phenyl]-furan-2-yl}-
nicotinamidine, is an oral prodrug that has shown promising efficacy in both mouse and monkey
models of second stage human African trypanosomiasis. However, gastrointestinal (GI) toxicity
was observed with high doses in a vervet monkey safety study. In the current study, we compared
the metabolism of DB844 by hepatic and extrahepatic cytochrome P450s to determine if
differences in metabolite formation underlie the observed GI toxicity. DB844 undergoes
sequential O-demethylation and N-dehydroxylation in the liver to form the active compound
DB820 (CPD-593-12). However, extrahepatic CYP1A1 and CYP1B1 produced two new
metabolites, MX and MY. Accurate mass and collision-induced dissociation mass spectrometry
analyses of the metabolites supported proposed structures of MX and MY. In addition, MY was
confirmed with a synthetic standard and detection of nitric oxide release when DB844 was
incubated with CYP1A1. Taken altogether, we propose that MX is formed by insertion of an
oxygen into the amidine C=N to form an oxaziridine, which is followed by intramolecular
rearrangement of the adjacent O-methyl group and subsequent release of nitric oxide. The
resulting imine ester, MX, is further hydrolyzed to form MY. These findings may contribute to
furthering the understanding of toxicities associated with benzamidoxime- and
benzmethamidoxime-containing molecules.
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Human African trypanosomiasis (HAT; or sleeping sickness), a parasitic infection, is fatal if
left untreated.1 During the first stage of HAT, Trypanosoma brucei(T. b.)gambiense and T.
b. rhodesiense are confined to the hemolymphatic system. The disease progresses to second
stage when parasites cross the blood-brain barrier and invade the central nervous system
(CNS), leading to the deterioration of neurological function and disruption of the sleep/wake
cycle, hence the name “sleeping sickness”. Drugs currently used to treat HAT suffer from
poor oral bioavailability and thus require intravenous or intramuscular administration.
Reliance on injectable medications, as well as equipped medical facilities to administer the
medications, makes it difficult to treat patients in rural Africa where HAT is endemic.2 In
addition, many of these drugs cause moderate to severe adverse effects. Melarsoprol, for
example, which is used to treat second stage HAT, causes fatal reactive encephalopathy in
up to 12% of treated patients.3 As a result, there is an urgent need to develop safer and orally
active drugs to treat HAT, especially second stage HAT.
Pentamidine is an effective first stage HAT treatment, but must be administered
intramuscularly to overcome low oral bioavailability. Due to minimal blood-brain barrier
permeability, it is not curative against second stage HAT.4 To enhance the oral
bioavailability of pentamidine and other amidine analogs, a prodrug approach has been
employed. The prodrug pafuramidine (DB289) was synthesized by methoxylating the two
amidine moieties of furamidine (DB75), a pentamidine analog.5–7 Pafuramidine exhibited
85-fold greater permeability across Caco-2 cell monolayers than furamidine.8 In addition, it
was biotransformed to the active compound DB75 in the liver and intestine via sequential O-
demethylation and N-dehydroxylation, reactions predominantly catalyzed by cytochrome
P450 (CYP) enzymes and cytochrome b5/NADH-cytochrome b5 reductase, respectively.9–12
Pafuramidine administered orally achieved an 89% cure rate against first stage HAT in a
phase III clinical trial; however, its development was later terminated due to unexpected,
delayed severe kidney injury in an expanded phase I safety trial.13
In an effort to discover orally active trypanocides for the treatment of second stage HAT, an
aza-analog of furamidine, DB820 (6-[5-(4-amidinophenyl)-furan-2-yl]nicotinamidine;
CPD-593-12) (Figure 1), and its methoxy prodrug, DB844 (N-methoxy-6-{5-[4-(N-
methoxyamidino)phenyl]-furan-2-yl}-nicotinamidine; CPD-594-12) (Figure 1), were
synthesized and their potential to treat second stage HAT tested. DB844 was relatively
inactive against trypanosomes, exhibiting an in vitro IC50 of 37 μM against T. b.
rhodesiense STIB900, thus indicating that biotransformation to the active compound
DB820, a potent trypanocide exhibiting an in vitro IC50 of 5.2–7.0 nM, is required.14,15 The
biotransformation of DB844 to DB820 occurs in the liver and involves sequential O-
demethylation and N-dehydroxylation16, similar to the biotransformation of pafuramidine.
DB844 administered orally was 100% curative in the chronic CNS (T. b. brucei GVR35)
mouse model, which mimics second stage HAT, but only approximately 40% (3/7 monkeys)
curative in the second stage HAT (T. b. rhodesiense KETRI 2537) vervet monkey
model.15,17 After the 14th daily oral dose of DB844 at 6 mg/kg in vervet monkeys, the
geometric mean (90% CI) maximum plasma concentration and terminal half-life of DB844
were 0.43 μM (0.1, 1.8 μM) and 0.24 day (0.14, 0.40 day), respectively.17 In the safety
portion of the vervet monkey study, higher oral DB844 doses (10 and 20 mg/kg body weight
daily for 10 days) elicited marked gastrointestinal (GI) abnormalities (ulceration and
inflammation), which were not observed with other methoxyamidine prodrugs (e.g.,
pafuramidine18 and DB86819). To determine why DB844 caused GI toxicity, we examined
DB844 metabolism by hepatic and extrahepatic CYP enzymes, as well as liver and intestinal
microsomes from monkeys and humans, subsequently identifying two novel metabolites
formed by extrahepatic CYP1A1 and CYP1B1, MX and MY. We have proposed herein a
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metabolic pathway involving intramolecular rearrangement and nitric oxide release that led
to the formation of MX and MY. These results may contribute to the understanding of




DB844, DB820, M1A (DB1284), M1B (DB1058), M2A (DB1285), M2B (DB1212), M3
(DB821), and deuterium-labeled DB844 analogs (Figure 1) were synthesized as previously
reported.14,20 Supersomes™, microsomes prepared from baculovirus-infected insect cells
expressing human CYP enzymes and NADPH-cytochrome P450 reductase, were purchased
from BD Biosciences (San Jose, CA). However, CYP2J2, CYP4F2, CYP4F3A, CYP4F3B,
and CYP4F12 Supersomes™ coexpressed both NADPH-cytochrome P450 reductase and
cytochrome b5. Corresponding control microsomes, prepared from insect cells infected with
either wild-type baculovirus or baculovirus containing cDNA-expressed human NADPH-
cytochrome P450 reductase and cytochrome b5, also were obtained from BD Biosciences.
Escherichia coli(E. coli) expressing human CYP1A1 and NADPH-cytochrome P450
reductase were custom prepared by Cypex, Ltd. (Dundee, Scotland, UK). Human liver
microsomes (HLM; mixed gender, pool of 200), human intestinal microsomes (HIM; mixed
gender, pool of 13), liver microsomes from cynomolgus monkeys treated with saline
(cynoLM-saline; male, pool of 3) or β-naphthoflavone (cynoLM-β-NF; male, pool of 4),
vervet monkey liver microsomes (vervet LM; male, custom-prepared) and vervet monkey
intestinal microsomes (vervet IM; male, custom-prepared) were purchased from XenoTech
LLC (Lenexa, KS). CynoLM-β-NF was reported by the vendor to have 8-fold higher 7-
ethoxyresorufin O-dealkylation (EROD) activity (2370 pmol/mg protein/min) than the
control cynoLM-saline. (4-Methoxycarbonylphenyl)boronic acid was obtained from Combi-
Blocks, Inc. (San Diego, CA). Ammonium formate, formic acid, trifluoroacetic acid (TFA),
β-NADPH, acetonitrile (HPLC-grade), water (HPLC-grade), and all other chemicals were
purchased from Sigma-Aldrich (St. Louis, MO) or Fisher Scientific (Pittsburgh, PA).
Metabolism of DB844 by Recombinant Human CYP Enzymes
The metabolism of DB844 by recombinant human CYP enzymes (1A1, 1B1, 1A2, 2C8,
2C9, 2C19, 2D6, 2J2, 3A4, 4F2, 4F3A, 4F3B and 4F12) was studied using a method
previously published for pafuramidine.10 Briefly, incubation mixtures (in triplicate)
contained DB844 (3 μM final concentration), recombinant CYP enzymes individually (50
pmol/mL), 100 mM phosphate buffer (pH 7.4), and 3.3 mM MgCl2. Reactions were initiated
by the addition of NADPH (1 mM final concentration) and allowed to proceed for 15 min at
37°C. Control incubations were conducted with control Supersomes™ (0.25 mg/mL) or in
the absence of NADPH. The reactions were stopped with half volume of ice-cold
acetonitrile containing 0.1% (v/v) formic acid. After centrifugation to pellet precipitated
proteins, the supernatants were analyzed by HPLC/UV and the % substrate consumed
(instead of metabolite formation) was calculated as sequential reactions occurred during the
15-min incubation. Recombinant CYP enzyme concentration and incubation time were
chosen to allow formation of primary and secondary metabolites before the complete
disappearance of the substrate.
Reactions for metabolite identification studies were conducted with sample preparation and
conditions similar to those described above, except that recombinant CYP enzymes were
added to give a final concentration of 10 pmol/mL for CYP1A1 (enzyme concentration was
lowered due to greater efficiency in metabolizing DB844) or 50 pmol/mL for CYPs 1B1 and
1A2. Samples that utilized deuterium-labeled analogs were concentrated 20-fold using
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Empore C18-SD SPE cartridges (Sigma-Aldrich). After loading the quenched reaction
mixture (2 mL), the membrane was washed five times with HPLC-grade water (1 mL). The
concentrated sample was eluted with acetonitrile (0.1 mL) and immediately dried under
nitrogen. The dried sample was reconstituted with 0.1 mL of 8% (v/v) acetonitrile
containing 35 mM formic acid and 15 mM ammonium formate prior to HPLC/UV and
HPLC/MS analyses.
Metabolism of DB844 by liver and intestinal microsomes
The metabolism of DB844 by liver and intestinal microsomes from humans and monkeys
was studied using a similar method as described above. Briefly, incubation mixtures (in
triplicate) contained DB844 (10 μM final concentration), 100 mM phosphate buffer (pH
7.4), and 3.3 mM MgCl2, and microsomes (1.0 mg/mL). Higher microsomal protein
concentrations were not tested due to limited microsomal stock concentrations, especially
for intestinal microsomes. Reactions were initiated by the addition of NADPH (1 mM final
concentration) and allowed to proceed for up to 30 min at 37°C. The reactions were stopped
with half volume of ice-cold acetonitrile at 0, 10, 20, and 30 min. After centrifugation to
pellet precipitated proteins, the supernatants were analyzed by HPLC/UV and DB844
metabolites were identified by comparing retention times to those of synthetic standards. A
positive control incubation with recombinant CYP1A1 (50 pmol/mg) was performed and
analyzed in parallel.
Biosynthesis of MX and MY
Cultures of E. coli expressing human CYP1A1 and NADPH-cytochrome P450 reductase
were used for the biosynthesis of the metabolites MX and MY for structural elucidation.
DB844 (25 μM final concentration) was added to a suspension of E. coli (200 pmol
CYP1A1/mL; 2 L per reaction) and the mixture incubated at 37°C for 30 min. Following
centrifugation at 13,000 rpm for 1 min to pellet the bacteria and terminate the reaction, the
supernatant was removed, mixed with an equal volume of acetonitrile and placed on ice. Ten
min later, the sample was centrifuged at 16,000 g for 1 min to pellet precipitated proteins.
The resulting supernatant (crude mixture) was stored in 50-mL aliquots at −80°C. To purify
MX and MY, the crude mixture (100 mL) was concentrated using Empore C18-SD SPE
cartridges. After loading the sample, the membrane was washed five times with HPLC-
grade water (1 mL) prior to elution of the concentrated sample with acetonitrile (0.5 mL).
The eluate was immediately dried under nitrogen and the remaining pellet stored at −80°C.
Prior to HPLC separation, the pellet was reconstituted with 0.5 mL of 8% (v/v) acetonitrile
containing 35 mM formic acid and 15 mM ammonium formate. MX and MY were separated
from the concentrated sample (0.4 mL) on a custom-packed semi-preparative HPLC column
(Zorbax Bonus-RP, 9.4 mm × 250 mm, 5 μm; Agilent, Santa Clara, CA) using a Varian
ProStar Prep HPLC System (Palo Alto, CA). Mobile phase (A) consisted of HPLC-grade
water with 35 mM formic acid and 15 mM ammonium formate; (B) consisted of 80:20 (v/v)
acetonitrile:HPLC-grade water with 35 mM formic acid and 15 mM ammonium formate.
The initial gradient condition was 10% B at a flow rate of 4 mL/min. Mobile phase B
increased linearly to 60% over 25 min and then to 100% over 3 additional min. After
washing with 100% B for 5 min, the system was re-equilibrated for 6 min with 10% B. UV
absorbance was monitored at 359 nm and the eluent collected in 30-second fractions using a
fraction collector. MX, M1A, and M1B eluted at approximately 14.4, 15.5, and 13.6 min,
respectively. Fractions that contained MX were further concentrated using Empore C18-SD
SPE cartridges. The final concentrated sample was reconstituted in 0.1 mL of 50% (v/v)
acetonitrile prior to storage at −80°C. MY was obtained by allowing a portion of purified
MX to hydrolyze under aqueous conditions.
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Chemical Synthesis of the Proposed MY Metabolite
To synthesize the proposed MY metabolite, a mixture of 2-bromo-5-(4-methoxyamidino-2-
pyridyl)furan (296 mg, 1.0 mmol; prepared as previously described14), (4-
methoxycarbonylphenyl)boronic acid (200 mg, 1.1 mmol), palladium acetate (10 mg, 4.5
mol%), and powdered potassium phosphate (420 mg, 2.0 mmol) in methanol (12 mL) was
stirred at room temperature under nitrogen for 3 h. The mixture was diluted with water to
give a green precipitate. The precipitate was filtered and washed with water.
Recrystallization from methanol (~200 mL, with concentration to ~50 mL) at room
temperature overnight gave orange/tan crystals (114 mg, 32 mol%; mp 231–234°C). IR
(cm−1): 3433, 3318, 3169, 2992, 2957, 2937, 2900, 2819, 1706, 1628, 1600, 1276, 1052,
1025, 912, 858, 796, 765, 695. 1H-NMR (DMSO-d6): 3.78 (s, 3H), 3.86 (s, 3H), 6.29 (br s,
NH2), 7.32 (d, J = 3.6Hz, 1H), 7.36 (d, J = 3.6Hz, 1H), 7.93–8.11 (m, 6H), 8.86 (m,
1H). 13C-NMR (DMSO-d6): 52.2, 60.8, 111.1, 112.1, 118.0, 123.8, 126.8, 128.4, 129.9,
133.8, 134.2, 147.0, 148.3, 149.0, 152.9, 153.3, 165.8. Analytical calculated for
C19H17N3O4•0.1CH3OH (MW 354.56 g/mol): C, 64.70; H, 4.95; N, 11.85. Observed: C,
64.61; H, 4.89; N, 11.61.
HPLC/UV Analysis
DB844 and its metabolites were separated on an Agilent ZORBAX Bonus-RP analytical
column (2.1 × 50 mm, 3.5 μm) at room temperature using an Agilent 1100 Series HPLC
system equipped with a UV diode array detector. Mobile phase (A) consisted of HPLC-
grade water with 35 mM formic acid and 15 mM ammonium formate; (B) consisted of 80:20
(v/v) acetonitrile:HPLC-grade water with 35 mM formic acid and 15 mM ammonium
formate. For HPLC/UV analysis of microsomal samples, the initial gradient condition was
5% B at a flow rate of 0.35 mL/min. Mobile phase B increased linearly to 80% over 15 min
and then the column was washed with 95% B for 1 min. The system was re-equilibrated for
6 min with 5% B with a total run time of 22 min. For HPLC/UV analysis of purified MX
and MY, the initial gradient condition was 10% B at a flow rate of 0.35 mL/min. Mobile
phase B increased linearly to 100% over 25 min. The system was re-equilibrated for 6 min
with 10% B prior to the next injection. All samples were monitored at a UV absorbance of
359 nm.
HPLC/MS Analyses
Initial qualitative characterization of DB844 metabolites and synthetic standards employed
an Agilent 1100 Series HPLC system equipped with a UV detector and coupled to an MSD
ion trap mass spectrometer (HPLC/ion trap MS; Agilent) as previously described.16 Samples
were separated on an Agilent ZORBAX Bonus-RP analytical column (2.1 × 150 mm, 5 μm)
at room temperature. Mobile phase (C) consisted of HPLC-grade water with 0.025% (v/v)
TFA; (D) consisted of 80:20 (v/v) acetonitrile:HPLC-grade water with 0.025% (v/v) TFA.
The initial gradient condition was 10% D at a flow rate of 0.35 mL/min. Mobile phase D
increased linearly to 60% over 25 min and then to 100% over 3 additional min. After
washing with 100% D for 5 min, the system was re-equilibrated for 6 min with 10% D. UV
absorbance was monitored at 359 nm prior to introduction into a pneumatically assisted
electrospray (ESI) interface operated in positive mode. Full-scan MS (molecular ion) and
auto MS/MS (MS2 and MS3 product ions) mass spectra were acquired on the ion trap mass
spectrometer using previously described instrument parameters.16
Accurate mass analysis was performed on an Agilent 6530 Accurate-Mass Quadrupole
Time-of-Flight (Q-TOF) LC/MS (HPLC/Q-TOF) to confirm the molecular formula and MS/
MS product ion elemental compositions. Samples were initially separated on an Agilent
1290 HPLC system with conditions similar to those described above for the HPLC/ion trap
MS work. Prior to analysis, the Q-TOF mass resolution, sensitivity and mass calibration
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were checked with the Agilent tune compound. The reference liquid was introduced into the
Q-TOF by an Agilent isocratic pump running at 0.7 mL/min with a 1:100 split, resulting in a
7 μL/min flow rate into the dual ESI source. Parameters for the ESI dual source were: drying
gas, 9 L/min of nitrogen; nebulization gas, 30 psi; sheath gas flow rate, 11 L/min; sheath gas
temperature, 350°C; drying gas temperature, 350°C; capillary voltage, 4000 V; nozzle
voltage, 1000 V; fragmentor voltage, 110 V; and CID collision gas, nitrogen. The instrument
was operated in auto MS/MS mode, scanning m/z 100–1000 using positive ion detection.
MS/MS spectra were acquired at collision energies of 10, 20, 40 and 60 V. The Agilent
tuning ions of m/z 121.05087 and m/z 922.00980 served as reference masses for exact mass
determination. The resulting data were processed using Agilent MassHunter Qualitative
analysis workstation software (version B.05).
Nitrate/Nitrite Formation Assay
The nitrate/nitrite fluorometric assay (Cayman Chemical Co., Ann Arbor, MI) was used to
quantify nitric oxide (NO) formation. NO has a very short half-life in biological systems, as
it is rapidly scavenged/oxidized to form the end-products nitrate and nitrite. To measure NO
formation following DB844 metabolism, DB844 (10 μM final concentration; in triplicate)
was incubated with recombinant CYP enzymes (CYP1A1, CYP1A2 or CYP1B1 at 50 pmol/
mL) or control Supersomes™ (0.25 mg/mL) for 1 h as described under Metabolism of
DB844 by Recombinant Human CYP Enzymes in Materials and Methods. Control
incubations were conducted with heat-inactivated enzymes (90°C for 5 min prior to addition
of DB844 and β-NADPH) or in the absence of recombinant CYP enzyme or DB844.
Reactions were stopped by heating the samples at 90°C for 5 min. The reaction mixtures
were transferred to Amicon Ultra-0.5 Centrifugal Filters with Ultracell-30 membrane (EMD
Millipore, Billerica, MA) and centrifuged at 14,000 g for 30 min to remove proteins. The
resulting filtrate was dried under vacuum using a CentriVap concentrator (Labconco Corp.,
Kansas City, MO) and reconstituted with the assay buffer provided in the kit. The assay was
performed according to the manufacturer’s protocol. Briefly, nitrate in the sample was
reduced to nitrite with nitrate reductase. Subsequent addition of 2,3-diaminonaphthalene
(DAN) resulted in the formation of 1(H)-naphthotriazole, the fluorescent product. Sodium
hydroxide was added to enhance the fluorescence of the final product. Samples were
measured at an excitation wavelength of 360 nm and an emission wavelength of 404 nm,
which had been optimized for minimal background signal from DB844 and β-NADPH. A
series of nitrite standard solutions (0.078–5.0 μM) were prepared for calibration curves.
Data Analysis
The percent substrate consumed in DB844 incubations with recombinant CYP enzymes was
determined after normalizing DB844 concentrations in these reactions to that in incubations
with control Supersomes™ (expressed as 0% substrate consumed) at 15 min. Differences in
average nitrate/nitrite concentrations between incubations with recombinant CYP enzymes
or control Supersomes™ and with heat-inactivated enzymes (negative controls) were
determined using unpaired, two-tailed Student’s t-tests (GraphPad Prism 5.04; GraphPad
Software, Inc., La Jolla, CA). Statistical outcomes were considered significant when the p-
value was <0.05.
RESULTS
Metabolism of DB844 by Recombinant Human CYP Enzymes
A panel of recombinant human CYP enzymes, comprised of hepatically and extrahepatically
expressed CYPs, was used to evaluate the metabolism of DB844 by individual CYP
isoforms. Activity was determined as the percent of substrate (DB844) consumed/depleted
during a 15-min incubation. DB844 was metabolized by multiple human CYPs in NADPH-
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dependent reactions (Figure 2; data not shown for NADPH-deficient reactions). CYP2J2
exhibited the greatest activity (96%), followed by CYP1A1 (90%), CYP1A2 (42%),
CYP4F2 (39%), CYP1B1 (30%), CYP4F3B (19%) and CYP3A4 (16%). The remaining
CYPs, 2C8, 2C9, 2C19, 2D6, 4F3A and 4F12, only showed marginal activity (<5%
substrate depletion). Neither control microsomes prepared from empty baculovirus-infected
insect cells nor from baculovirus-infected insect cells expressing NADPH-cytochrome P450
reductase and cytochrome b5 could metabolize DB844 (data not shown).
Incubation of DB844 (m/z 366.2) with hepatic CYP enzymes (i.e., CYPs 1A2, 3A4, 2J2, 4F2
and 4F3B) resulted in the expected O-demethylation metabolites, M1A (m/z 352.2), M1B
(m/z 352.2) and M3 (m/z 338.2; from double O-demethylation), as identified by comparison
of HPLC retention times and MS/MS fragmentation patterns to those of synthetic standards.
A representative HPLC/UV chromatogram from an incubation with CYP1A2 is shown in
Figure 3A. These O-demethylation metabolites are the same as those detected when DB844
was incubated with HLM.16 However, the N-dehydroxylation metabolites formed in HLM
(e.g., M2A and M2B which elute between M3 and M1B; Figure 4A) were not observed in
incubations with the recombinant human CYP enzymes (Figure 3A), presumably because
the Supersomes™ used in the current studies lacked NADH-cytochrome b5 reductase
expression.11,21
Incubation of DB844 with the extrahepatic enzymes CYP1A1 and CYP1B1 resulted in two
novel metabolites, MX and MY (Figures 3B and 3C, respectively). HPLC/ion trap MS
analysis revealed that MX had a molecular ion of m/z 351.2, suggesting a loss of NH (15
Da) from DB844 (m/z 366.2) rather than the loss of CH2 (14 Da) that results in M1A (m/z
352.2) and M1B (m/z 352.2). Initial HPLC/ion trap MS analysis was unable to provide
parent ion information for MY due to low abundance and high background noise.
Metabolism of DB844 by liver and intestinal microsomes from humans and monkeys
To determine metabolite profiles of DB844 in liver and intestinal microsomes from humans
and monkeys, incubation mixtures were analyzed by HPLC/UV and representative
chromatograms for 30-min incubations are shown in Figure 4. Pooled HLM, pooled HIM,
vervet LM and vervet IM produced similar metabolite profiles (Figures 4A–D), consisting of
primary O-demethylation metabolites (M1A and M1B), secondary N-dehydroxylation
metabolites (M2A and M2B), and double O-demethylation metabolite (M3). Neither MX
nor MY was detected in these reactions (data for shorter incubations are not shown).
However, when liver microsomes prepared from β-NF-treated cynomolgus monkeys were
used, MX and MY were generated in DB844 incubations (Figure 4E). In contrast, neither
MX nor MY was detected in incubations with saline-treated cynomolgus liver microsomes
(data for shorter incubations are not shown) (Figure 4F). In positive control incubation with
recombinant CYP1A1, MX and MY eluted at 7.6 and 11.6 min, respectively (data not
shown).
Biosynthesis and Characterization of MX and MY
In order to determine more detailed structural information for the novel metabolites, MX
and MY were purified from incubations of DB844 with E. coli expressing CYP1A1. MX
was unstable and converted to MY during both the concentration/purification process and in
the reconstitution solvent (50% (v/v) acetonitrile). This was evidenced by 1) the detection of
MY in semi-preparative HPLC fractions that were expected to only contain MX due to good
HPLC separation between MX and MY (14.4 vs. 28.2 min; Figure 5) and 2) the MX peak in
the HPLC/UV chromatogram decreased following a 6-h incubation in reconstitution solvent
at room temperature while the MY peak increased (Figure 5). These results indicate that MX
is not chemically stable and degrades to MY.
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The accurate masses (and formulae) of MX and MY were determined to be 350.1377 Da
(C19H18N4O3) and 351.1229 Da (C19H17N3O4), respectively. The molecular ion clusters of
MX and MY exhibited isotopic distributions matching those predicted (Figures 6A and 6C).
Collision-induced dissociation (CID) fragmentation of the MX molecular ion [MX+H]+
produced a predominant product ion with m/z 304.1086 (C18H14N3O2), corresponding to the
loss of OCH3NH2 (loss of 47 Da) (Figure 6B). CID fragmentation of the MY molecular ion
[MY+H]+ produced a predominant product ion with m/z 305.0927 (C18H13N2O3),
corresponding to the loss of OCH3NH2 (Figure 6D).
MS2 and MS3 Analyses of MX and MY
Purified MX and MY from biosynthesis and M1B synthetic standard were analyzed by
HPLC-ion trap MS; the MS2 and MS3 mass spectra are presented in Figure 7. CID
fragmentation of the M1B molecular ion [M1B+H]+ (m/z 352.2) produced one major
product ion with m/z 305.1, corresponding to the characteristic loss of OCH3NH2 (loss of 47
Da) from the methoxyamidine on the pyridine ring side, and two minor product ions with m/
z 321.2 and m/z 335.1, corresponding to the loss of OCH3 (loss of 31 Da) and NH3 (loss of
17 Da), respectively (Figure 7A). The m/z 305.1 product ion underwent further CID
fragmentation, resulting in several MS3 product ions that included a major ion with m/z
288.0 (loss of NH3 from the amidoxime side; 17 Da) and a minor ion with m/z 272.1 (loss of
OHNH2 from the phenyl ring amidoxime side; 33 Da).
[MX+H]+ (m/z 351.2) was 1 Da less than [M1B+H]+ (Figure 7B). CID fragmentation of
[MX+H]+ produced one major product ion with m/z 304.1, corresponding to the
characteristic loss of OCH3NH2 from the methoxyamidine moiety. The m/z 304.1 product
ion underwent further CID fragmentation, resulting in two major MS3 product ions with m/z
289.0 (loss of CH3; 15 Da) and m/z 272.0 (loss of OHCH3; 32 Da).
[MY+H]+ (m/z 352.2; Figure 7C) has the same molecular weight as M1A and M1B. CID
fragmentation of [MY+H]+ produced one major product ion with m/z 305.1, corresponding
to the characteristic loss of OCH3NH2 from the methoxyamidine moiety. The m/z 305.1
product ion underwent further CID fragmentation, resulting in two major MS3 product ions
with m/z 273.0 (loss of OHCH3; 32 Da) and m/z 245.0 (loss of 60 Da).
Determination of the Site of Metabolism using Deuterium-labeled DB844
To determine the site of metabolism that results in MX and MY formation, deuterium-
labeled DB844 analogs (DB844-pyridyl-CD3, DB844-phenyl-CD3, and DB844-D4; Figure
1) were individually incubated with recombinant CYP1A1. MX formed from DB844-
pyridyl-CD3 exhibited a molecular ion of m/z 354.1 in HPLC/ion trap MS analysis (Figure
8A). This is 3 Da greater than MX formed from unlabeled DB844 (Figure 7B), indicating
that the three deuterium atoms on the pyridine side were retained in MX. CID fragmentation
of the m/z 354.1 molecular ion generated a MS2 product ion with m/z 303.9, corresponding
to the characteristic loss of OCD3NH2 from the methoxyamidine on the pyridine ring side
(loss of 50 Da). Further fragmentation of the m/z 303.9 ion produced several MS3 product
ions (m/z 288.8 and 271.8) similar to those produced from unlabeled MX. These results
suggest that the methyl group on the pyridine ring side of DB844 remains intact in MX.
MX formed from DB844-phenyl-CD3 exhibited a molecular ion of m/z 354.1 (Figure 8B),
which is 3 Da greater than MX formed from unlabeled DB844, indicating that the three
deuterium atoms on the phenyl side were retained in MX as well. CID fragmentation of the
m/z 354.1 molecular ion gave rise to a major MS2 product ion with m/z 307.0, corresponding
to the characteristic loss of OCH3NH2 from the methoxyamidine on the pyridine ring side
(loss of 47 Da). If such a loss had occurred from the methoxyamidine on the phenyl ring
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side, it would have resulted in a loss of 50 Da (OCD3NH2), forming a product ion with m/z
304.1. This product ion was not detected, further confirming that the methyl group on the
pyridine ring side of DB844 remains intact in MX. Further fragmentation of the m/z 307.0
ion produced two MS3 product ions (m/z 288.9 and 271.9) similar to those generated from
unlabeled DB844 (Figure 7B) and DB844-pyridyl-CD3 (Figure 8A). These findings indicate
that the loss of 18 Da (m/z 307.0 → 288.9) was due to the loss of CD3, suggesting that the
methyl group on the phenyl ring side of DB844 also remains in MX, but not as a
methoxyamidine. This was further supported by HPLC/ion trap MS analysis of MY
molecules formed from DB844-pyridyl-CD3 and DB844-phenyl-CD3 (data not shown).
Finally, HPLC/ion trap MS analysis of MX formed from DB844-D4 (deuterated phenyl
ring) showed a molecular ion of m/z 355.2 and a MS2 product ion with m/z 308.1 (Figure
8C). These were 4 Da greater than the MX molecular ion and product ion formed from
unlabeled DB844, indicating that the phenyl ring remains unaltered in MX.
Proposed Reaction Mechanism and Structures of MX and MY
Based on the HPLC/ion trap MS analysis of MX and MY described above, we have
proposed a reaction mechanism for the formation of MX and MY from DB844 catalyzed by
CYP1A1 and CYP1B1 (Scheme 1). CYP1A1 and CYP1B1 catalyze the insertion of oxygen
into the C=N bond on the phenyl ring side of the molecule, forming an oxaziridine
intermediate. Intramolecular rearrangement of the adjacent O-methyl bond follows and nitric
oxide is subsequently released. The proposed intramolecular rearrangement of the adjacent
O-methyl bond results in the formation of MX, an imine ester, which is further hydrolyzed
to form the corresponding ester MY.
To support the proposed reaction mechanism and structures of MX and MY, an authentic
MY standard was synthesized based on the proposed structure in Scheme 1. Synthetic MY
eluted at the same time as purified MY from biosynthesis when analyzed by HPLC/ion trap
MS (Figure 9A). CID fragmentation of synthetic MY produced a molecular ion of m/z 352.2
and one major MS2 product ion with m/z 305.1. Further fragmentation produced several
MS3 product ions (m/z 273.0 and 245.0) (Figure 9B). This CID fragmentation pattern was
similar to that exhibited by purified MY from biosynthesis under the same conditions
(Figure 7C).
Nitric Oxide Formation
To further support the proposed reaction mechanism, the formation of nitric oxide was
determined by quantifying the total amount of nitrate and nitrite present in incubations of
DB844 with recombinant human CYP enzymes. Background signals were determined in
incubations without the addition of CYP enzyme or DB844. Significant nitric oxide
formation was detected in incubations with CYP1A1, but not with CYP1A2, CYP1B1 or
control Supersomes, when compared to incubations with heat-inactivated enzymes (Figure
10).
DISCUSSION
DB844 is a novel oral prodrug that has shown promising efficacy in the mouse and monkey
models of second stage HAT.15,17 This compound undergoes complex biotransformation
involving sequential O-demethylation and N-dehydroxylation reactions to form the active
antitrypanosomal diamidine DB820 in HLM.16 After oral administration of DB844 at a
daily dose of 6 mg/kg in vervet monkeys, maximum plasma concentration of DB844
reached approximately 1–2 μM after the 14th dose and presumably even higher when 10 and
20 mg/kg daily doses were used in safety testing.17 Hence DB844 substrate concentrations
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(3 and 10 μM) used in this study are relevant to in vivo drug exposures. Human hepatic CYP
enzymes, including CYPs 1A2, 2J2, 3A4, 4F2 and 4F3B, catalyzed the initial O-
demethylation of DB844 to form M1A and M1B (Figure 2). These same enzymes also
catalyzed the initial O-demethylation of pafuramidine (DB289) to form M1 (DB775) in the
human liver.10 Given the similarity between chemical structures of DB844 (Figure 1) and
pafuramidine, it is presumed that CYP4F enzymes, as well as CYP3A4 and CYP1A2, play a
predominant role in catalyzing the O-demethylation of DB844 in the human liver. Further
reaction phenotyping studies employing selective chemical inhibitors, inhibitory antibodies,
and correlation analysis are needed to confirm this.
In addition to catalyzing the O-demethylation of DB844, the extrahepatic CYP enzymes
CYP1A1 and CYP1B1 generated two additional metabolites, MX and MY (Figure 3). These
metabolites were not formed by hepatic CYP enzymes (i.e., CYPs 1A2, 2J2, 3A4, 4F2 and
4F3B), explaining why neither was detected in incubations with HLM (Figure 4A). It was
imperative to identify MX and MY since 1) it may help to assess the potential toxicity
liability of these two metabolites in extrahepatic tissues that are known to express CYP1A1
and/or CYP1B1 (e.g., small intestine22 and lung23), and 2) it may serve as a marker reaction
for CYP1A1 and CYP1B1 since CYP1A2 and other CYP enzymes examined in this study
did not form MX or MY. Biosynthesized MX and MY, as well as authentic MY standard,
were subsequently characterized using HPLC/ion trap MS fragmentation and HPLC/Q-TOF
accurate mass analysis to elucidate their chemical structures. First, MX was found to be
unstable and chemically degraded to MY. Second, there were clear differences between CID
fragmentation patterns of MX, MY, and the O-demethylation metabolite M1B. Although
similar fragmentation patterns were seen in the MS2 mass spectra (i.e., characteristic loss of
OCH3NH2 (47 Da) from the methoxyamidine group), further fragmentation (MS3) resulted
in different product ions, loss of NH3 (17 Da) from M1B, CH3 radical (15 Da) from MX,
and HOCH3 (32 Da) from MY (Figure 7). Finally, the site at which DB844 is metabolized to
form MX and MY was determined by employing deuterium-labeled DB844 analogs to
probe potential reaction locations at the methyl group on the pyridine ring side, the methyl
group on the phenyl ring side, and the phenyl ring (Figure 8). Our results suggest that both
the methyl group on the phenyl ring side and on the pyridine ring side of DB844 were
retained in MX. In addition, the methyl group on the phenyl ring side did not exist as
methoxyamidine in MX. Upon consideration altogether, we have proposed an atypical CYP
reaction mechanism that results in the formation of MX and MY from DB844 by CYP1A1
and CYP1B1 (Scheme 1). CYP1A1 and CYP1B1 introduce an oxygen atom into the
amidine C=N bond of DB844, forming an oxaziridine intermediate. The intermediate
undergoes intramolecular rearrangement of the adjacent O-methyl bond to produce MX, an
imine ester, and release one molecule of nitric oxide. MX is further hydrolyzed in aqueous
conditions to form the corresponding ester MY, which was confirmed using a synthetic
standard based on the proposed MY structure (Figure 9). Furthermore, nitric oxide
formation was detected in incubations of DB844 with recombinant CYP1A1 (Figure 10). In
conclusion, our experimental evidence strongly supports the proposed reaction mechanism
for CYP1A1/1B1-mediated MX and MY formation via intramolecular rearrangement
(Scheme 1).
To evaluate if nitric oxide formation via conversion of DB844 to MX is a potential
mechanism for the GI toxicity observed in DB844-treated vervet monkeys,17 DB844
metabolite profiles were determined using liver and intestinal microsomes from monkeys
and humans. Neither MX nor MY was detected in incubations with liver or intestinal
microsomes from humans and vervet monkeys (Figures 4A–D), indicating that nitric oxide
formation via conversion of DB844 to MX is unlikely a cause of the observed GI toxicity.
However, both MX and MY were detected in liver microsomes prepared from β-NF-treated
cynomolgus monkeys, but not from saline-treated control monkeys (Figures 4E and 4F). β-
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NF is known to induce human CYP1A1 and CYP1A2.24 Cynomolgus monkey CYP1A1 and
CYP1A2 are highly homologous to human counterparts and CYP1A1 has been reported to
be expressed in both cynomolgus monkey liver and intestine.25,26 Thus, induction of
cynomolgus monkey CYP1A1 likely explains the increased formation of MX in β-NF-
treated cynomolgus liver microsomes. It would be interesting to examine if MX formation
can be detected in β-NF-treated cynomolgus intestinal microsomes. Unfortunately, such
intestinal microsomes were not available from the vendor. Taken together, nitric oxide
formation via conversion of DB844 to MX may not explain the observed GI toxicity, but
possibility exists where an elevated CYP1A1/1B1 due to induction (e.g., by dietary
phytochemicals27) leads to MX formation and nitric oxide release from DB844.
It is not yet known if this intramolecular rearrangement and resulting nitric oxide release can
occur with other amidine analogs (e.g., benzamidoximes/N-hydroxylated benzamidines). If
true, it may contribute to the understanding of toxicity caused by other benzamidoxime- or
benzmethamidoxime-containing molecules, such as ximelagatran, a direct thrombin
inhibitor that failed in clinical trials due to idiosyncratic liver injury.28
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Structures of DB844, DB820, intermediate metabolites, and deuterium-labeled DB844
analogs.
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Figure 2. DB844 substrate depletion by recombinant human CYP enzymes
DB844 (3 µM) was incubated with 1 mM β-NADPH and either recombinant CYP enzymes
individually (50 pmol/mL) or control Supersomes™ (0.25 mg/mL) for 15 min at 37°C. The
percentage of DB844 consumed at the end of the reaction was determined by normalizing
the DB844 concentration in recombinant CYP enzyme incubations to that with control
Supersomes™ (expressed as 0%). Bars and error bars represent the means and standard
errors, respectively, of triplicate determinations.
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Figure 3. HPLC/UV chromatograms of DB844 incubated with recombinant human CYP1A2 (A),
CYP1A1 (B), and CYP1B1 (C)
DB844 (3 µM) was incubated with 1 mM β-NADPH and either 50 pmol/mL CYP1A2 or
CYP1B1, or 10 pmol/mL CYP1A1 for 15 min at 37°C. Quenched reaction mixtures were
analyzed by HPLC/ion trap MS as described under Materials and Methods. M1A, M1B, and
M3 were identified by comparing retention times and MS fragmentation patterns to those of
authentic standards. The molecular ions ([M+H]+; m/z) of DB844 and detected metabolites
are indicated next to the corresponding HPLC/UV peaks.
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Figure 4. HPLC/UV chromatograms of DB844 incubated with pooled HLM (A), pooled HIM (B),
vervet LM (C), vervet IM (D), cynoLM-β-NF (E) and cynoLM-saline (F)
DB844 (10 µM) was incubated with 1 mM β-NADPH and 1.0 mg/mL liver or intestinal
microsomes for 30 min at 37°C. Quenched reaction mixtures were analyzed by HPLC/UV
as described under Materials and Methods. *, unidentified metabolites; #, background
peaks.
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Figure 5. HPLC/UV chromatogram of biosynthesized MX after purification
MX was biosynthesized and purified as described under Materials and Methods. Purified
MX was concentrated using an Empore C18-SD SPE cartridge, dried down, and
reconstituted in 0.1 mL of 50% (v/v) acetonitrile. The reconstituted sample was immediately
analyzed (0 h) by HPLC/UV or kept at room temperature for 6 h prior to analysis.
Chromatograms are plotted on the same UV absorbance scale to facilitate the comparison of
peak heights.
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Figure 6. Accurate mass analysis of MX (A and B) and MY (C and D) by HPLC/Q-TOF
MX and MY were generated from incubations of DB844 (3 μM) with recombinant CYP1A1
(50 pmol/mL). Quenched reaction mixtures were separated on an analytical column prior to
introduction into a high resolution Q-TOF mass spectrometer for MS full scan (A and C)
and CID fragmentation analysis (B and D). Boxes with dotted lines denote the predicted
isotopic abundance based on the assigned formula for MX (C19H18N4O3) and MY
(C19H17N3O4), matching with the observed ion abundance of corresponding mass-to-charge
ratio.
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Figure 7. HPLC/ion trap MS analysis of authentic M1B standard (A) and biosynthesized MX (B)
and MY (C)
Samples were separated on an analytical column prior to introduction into an electrospray
interface and analysis by an ion trap MS to obtain MS full scan (top panel), MS2 (middle
panel) and MS3 (bottom panel) CID fragmentation mass spectra. The molecular ions and the
most intense product ions are denoted in bold. Ions that were selected for CID fragmentation
are denoted by a diamond symbol. Characteristic mass losses upon fragmentation are
provided, as are corresponding chemical formula for the proposed mass loss in parenthesis.
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Figure 8. HPLC/ion trap MS analysis of MX formed from DB844-pyridyl-CD3(A), DB844-
phenyl-CD3 (B), or DB844-D4(C)
Deuterium-labeled DB844 analogs (3 μM) were incubated with recombinant CYP1A1 (10
pmol/mL) for 15 min at 37°C. Quenched reaction mixtures were separated on an analytical
column prior to introduction into an electrospray interface and analysis by an ion trap MS to
obtain MS full scan (top panel), MS2 (middle panel) and MS3 (bottom panel) CID
fragmentation mass spectra. The molecular ions and most intense product ions are denoted
in bold. Ions that were selected for CID fragmentation are denoted by a diamond symbol.
Characteristic mass losses upon fragmentation are provided, as are corresponding chemical
formula for the proposed mass loss in parenthesis.
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Figure 9. HPLC/UV and HPLC/ion trap MS analyses of chemically synthesized and
biosynthesized MY
(A) HPLC/UV chromatograms of chemically synthesized (authentic standard; top panel) and
biosynthesized (bottom panel) MY. (B) MS full scan (top panel), MS2 (middle panel), and
MS3 (bottom panel) CID fragmentation mass spectra of chemically synthesized MY.
Comparison of HPLC retention times and CID fragmentation patterns for synthetic MY and
biosynthesized MY to those in Figure 6C support the proposed structure of MY.
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Figure 10. Nitric oxide formation in incubations of DB844 with recombinant human CYP
enzymes
DB844 (10 µM) was incubated with 1 mM β-NADPH and either recombinant CYP1A1,
CYP1A2, or CYP1B1 (50 pmol/mL) or control Supersomes (0.25 mg/mL) for 1 h. Nitric
oxide formation was determined by measuring the total concentration of nitrate and nitrite
present in each reaction mixture. Negative controls consisted of incubating DB844 with
enzymes that had been heat-inactivated (90°C for 5 min). Incubations without enzyme (but
with DB844 and β-NADPH) or without DB844 (but with CYP1A1 and β-NADPH) served
as additional controls. The left bar of each pair represents nitric oxide formation in negative
controls, while the right bar represents formation in incubations with active enzyme. Bars
and error bars represent the means and standard errors, respectively, of triplicate
determinations. Statistical differences in nitric oxide formation between negative controls
and incubations with active enzymes were evaluated by unpaired, two-tailed Student’s t-
tests. ***, p<0.001, incubation with active vs. heat-inactivated CYP1A1.
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Proposed reaction mechanism of CYP1A1/1B1-mediated MX and MY formation from
DB844: intramolecular rearrangement and release of nitric oxide.
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